ClinicalTrials.gg
RecruitingNCT07429006Updated Oct 6, 2026

SAD and MAD Study of AKB-9090 in Healthy Adult Participants

A Phase 1 interventional study of AKB-9090 and Placebo in Healthy Volunteers, sponsored by Akebia Therapeutics. Recruiting at 1 site in New Zealand. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Akebia Therapeutics · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Oct 6, 2026Study contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This is a first-in-human (FIH study designed to evaluate safety, tolerability, pharmacokinetic, and pharmacodynamic effects of AKB-9090 in healthy adult participants. The study consists of two stages: Stage 1, a single ascending dose (SAD) phase with four dose cohorts, and Stage 2, a multiple ascending dose (MAD) phase with one dose cohort. Approximately 32 participants in SAD and 12 in MAD are planned to be enrolled.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • AKB-9090
  • Single-centre
  • Single Ascending Dose
  • Multiple Ascending Dose
  • First-in-human
  • Safety
  • Tolerability
  • Randomized
  • Double-blind
  • Healthy Volunteers
03

In context

Lead sponsor

Akebia Therapeutics is the lead sponsor of 37 studies on the registry; 3 are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 12 (55%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Healthy adult participants with no findings, as judged by the investigator, based on physical examination, 12-lead , alcohol breath test, and clinical laboratory tests (including serum chemistry, hematology, coagulation, urine drug screen, and urinalysis).
  • (BMI) greater than 18.5 and less than 32.0 kg/m\^2 at screening.
  • In the Investigator's opinion, willing and able to provide written and comply with the all protocol requirements, including required confinement, outpatient visits, and protocol-specified restrictions (including refraining from major lifestyle changes) from signature of the informed consent form (ICF) through the last study visit.

Key Exclusion Criteria:

  • Clinically significant metabolic, hepatic, renal, hematologic, pulmonary, cardiovascular, gastrointestinal, musculoskeletal, dermatologic, urogenital, ophthalmologic, ear/nose/throat, psychiatric, or neurologic disorder.
  • History of active or recurrent within 2 years before screening or during the screening period, or currently receiving treatment or suppressive therapy for cancer, except for:

    1. Treated basal cell carcinoma of the skin
    2. Curatively resected squamous cell carcinoma of the skin
    3. Treated colonic or cervical carcinoma in situ
  • Abnormal ECG findings at screening, including:

    1. Severe bradycardia (heart rate \<40 beats per minute) on any measurement
    2. Mean Using Fridericia's Formula (QTcF) >450 msec for males or >470 msec for females
  • Elevated laboratory values (>1.25 × [ULN]) for (ALT), aspartate aminotransferase (AST), or creatinine at the screening visit or at check-in.
  • Evidence of acute or chronic (positive hepatitis B surface antigen) or infection (positive hepatitis C antibody and positive hepatitis C ribonucleic acid [RNA] test).
  • Use of nicotine-containing products (including cigarettes, cigars, tobacco, gum, patches, vaping, and e-cigarettes), caffeine-containing foods or beverages, and alcohol-containing foods or beverages during study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    AKB-9090

    Participants will receive a single intravenous (IV) dose of AKB-9090 at 4 escalating dose levels in the SAD stage and at 1 dose level in the MAD stage.

    Drug: AKB-9090

  • Placebo comparator
    Placebo

    Single IV dose of matching Placebo.

    Other: Placebo

Interventions

  • DrugAKB-9090

    AKB-9090 will be administered intravenously

  • OtherPlacebo

    Matching Placebo administered intravenously

06

What researchers measure

Primary outcomes

  1. Number of participants who will report serious Treatment emergent adverse events (TEAEs) and TEAEs

    Time frame: From First Dose to Day 7

  2. Number of Participants with Clinically Significant Changes in Physical Examinations

    Time frame: From First Dose to Day 7

  3. Number of Participants with Clinically Significant Changes in Vital Signs

    Time frame: From First Dose to Day 7

  4. Number of Participants with Clinically Significant Changes in 12-lead Electrocardiogram (ECG)

    Time frame: From First Dose to Day 7

  5. Number of Participants with Clinically Significant Changes in Chemistry parameters

    Time frame: From First Dose to Day 7

  6. Number of Participants with Clinically Significant Changes in Hematology Parameters

    Time frame: from first dose to Day 7

  7. Number of Participants with Clinically Significant Changes in Lipid Parameters

    Time frame: From First Dose to Day 7

  8. Number of Participants with Clinically Significant Changes in Coagulation Parameters

    Time frame: From First Dose to Day 7

  9. Number of Participants with Clinically Significant Changes in Urinalysis Parameters

    Time frame: From First Dose to Day 7

Secondary outcomes

  1. Stage 1 SAD Cohorts: Maximum observed plasma concentration (Cmax) of AKB-9090

    Time frame: At Day 1

  2. Stage 1 SAD Cohorts: Time of maximum plasma concentration (Tmax) of AKB-9090

    Time frame: At Day 1

  3. Stage 1 SAD Cohorts: Area under concentration time curve (AUC) from time 0 to the last observation (AUClast) of AKB-9090

    Time frame: At Day 1

  4. Stage 1 SAD Cohorts: Apparent body clearance (CL) of AKB-9090

    Time frame: At Day 1

  5. Stage 1 SAD Cohorts: AUC from time 0 to infinity (AUCinf) of AKB-9090

    Time frame: At Day 1

  6. Stage 1 SAD Cohorts: Terminal half-life (T1/2) of AKB-9090

    Time frame: At Day 1

  7. Stage 2 MAD Cohorts: Cmax of AKB-9090

    Time frame: At Day 1 and Day 7

  8. Stage 2 MAD Cohorts: Tmax of AKB-9090

    Time frame: At Day 1 and Day 7

  9. Stage 2 MAD Cohorts: AUC to 24 hours post-dose (AUC24) of AKB-9090

    Time frame: At Day 1

  10. Stage 2 MAD Cohorts: CL of AKB-9090

    Time frame: At Day 1 and Day 7

  11. Stage 2 MAD Cohorts: T1/2 of AKB-9090

    Time frame: At Day 1 and Day 7

  12. Stage 2 MAD Cohorts: AUC at Steady state (AUCss) of AKB-9090

    Time frame: At Day 7

  13. Stage 1 SAD Cohorts: Change from Baseline in Pharmacodynamic Biomarker - Erythropoietin (EPO)

    Time frame: Baseline (Day 1) and at 6, 12, 18, and 24 hours post-dose

  14. Stage 1 SAD Cohorts: Change from Baseline in Pharmacodynamic Biomarker - Red Blood Cell Count (RBC)

    Time frame: Baseline (Day 1) and At Days 2, 8, and 13

  15. Stage 1 SAD Cohorts: Change from Baseline in Pharmacodynamic Biomarker - Reticulocyte Count

    Time frame: Baseline (Day 1) and At Days 2, 8, and 13

  16. Stage 2 MAD Cohorts: Change from Baseline in Pharmacodynamic Biomarker - EPO

    Time frame: Baseline (Day 1 and Day 7) and at 6, 12, 18, and 24 hours post-dose

  17. Stage 2 MAD Cohorts: Change from Baseline in Pharmacodynamic Biomarker - RBC

    Time frame: Baseline (Day 1) and At Days 4, 8, 14, and 21

  18. Stage 2 MAD Cohorts: Change from Baseline in Pharmacodynamic Biomarker - Reticulocyte Count

    Time frame: Baseline (Day 1) and At Days 4, 8, 14, and 21

07

Study locations

1 of 1 sites recruiting
  • Investigator Site #1
    Auckland, New Zealand
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2026
First posted
Feb 24, 2026
StartActual
Mar 16, 2026
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Contact
Study contact changed: p•••@nzcr.co.nz · •••3474→s•••@nzcr.co.nz · •••3474. See the current contact
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Contact Study contact changed: p•••@nzcr.co.nz · •••3474→s•••@nzcr.co.nz · •••3474. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07429006
Collaborators
Emerald Clinical Trials
Responsible party
Sponsor
First posted
Feb 24, 2026
Start date
Mar 16, 2026
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Oct 6, 2026

Study contacts

Dr. Sophie Mckellar
Contact
sophie.mckellar@nzcr.co.nz
+64 9 373 3474
Dr. Sophie Mckellar sophie.mckellar@nzcr.co.nz
study director · New Zealand Clinical Research (NZCR)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion